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 The Human transcriptional 
positive coactivator 4 or PC4 activates 
several p53 dependent genes. It has been 
demonstrated that this is a consequence of 
direct interaction with p53. Previously, 
we have concluded that PC4 interacts 
mainly with the C-terminal negative 
regulatory domain of p53 through its 
DNA binding C-terminal half. NMR 
chemical shift perturbation studies with 
peptide fragments indicated that amino 
acids 380-386 of p53 are crucial for 
interaction with PC4. This was verified by 
fluorescence anisotropy and 
sedimentation velocity studies. A peptide 
consisting of p53 (380-386) sequence, 
when attached to a cell penetration tag 
and nuclear localization signal, localizes 
to the nucleus and inhibits luciferase gene 
expression from a transfected plasmid 
carrying a Luc gene under a p53 
dependent promoter. Acetylation of 
lysine-382/381 enhanced the binding of 
this peptide to PC4 by about an order of 
magnitude. NMR and mutagenesis studies 
indicated that Serine-73 of PC4 is an 
important residue for recognition of p53. 
Intermolecular nuclear Overhauser effect 
placed aspartate-76 in the vicinity of 
lysine-381, indicating that the region 
around residues 73-76 of PC4 is 
important for p53 recognition. We 
conclude that the 380-386 region of p53 
interacts with the region around residues 
73-76 of PC4 and acetylation of lysine-
382/381 of p53 may play an important 
role in modulating p53-PC4 interaction 
and as a consequence PC4 mediated 
activation of p53 target genes.  
 p53 is a well known tumor 
suppressor which is essential for cellular 
integrity and homeostasis. Under normal 
conditions, p53 is a very short lived protein 
and in normal cells it is present in low 
amounts; upon genotoxic insult like DNA 
damage, hypoxia, expression or over-
expression of oncogenes and nucleotide 
deprivation the levels of p53 is elevated as it 
is stabilized by various factors. Several post-
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translational modifications (acetylation, 
phosphorylation, methylation, ubiquitination 
and sumoylation) regulate p53 activation 
and stabilization (1). p53 is regulated by 
diverse pathways and has many interacting 
partners. Various interacting partners of p53 
positively or negatively regulate its stability 
and function.  For example, MDM2, COP I 
and PirH2 negatively regulate p53 by 
promoting its ubiquitination, whereas 
p19ARF and HAUSP positively regulate 
p53 function by preventing MDM2-p53 
interaction and enhance deubiquitination (2-
7). Lesser number of proteins is known 
which directly interact with p53 and 
positively regulate its functions without 
modifying the p53-MDM2 interactions. 
Some of these proteins are highly abundant 
nuclear proteins often associated with 
chromatin. These include the High-mobility-
group protein B1 (HMGB1)(8) and PC4. 
PC4 is a multifunctional, highly 
abundant nuclear protein originally 
discovered as a transcriptional coactivator 
that activates activator-dependent DNA 
transcription through RNA polymerase II 
(9). It plays crucial roles in transcription, 
replication, DNA repair, and normal cellular 
growth. PC4 stimulates ligase-mediated 
DNA end joining thus acting as an activator 
of non-homologous end joining and DSB 
repair activity (10). It binds non-specifically 
to single and double stranded DNA (11,12). 
The dsDNA binding ability of PC4 is 
essential for its coactivator function. 
Recently, it has been shown to be a bona 
fide non-histone component of chromatin 
which plays important role in chromatin 
compaction and plays a crucial role in 
maintaining the dynamic chromatin 
organization, and heterochromatin gene 
silencing. It is present in all stages of cell 
cycle (13,14). Mechanistically, PC4 directly 
interacts with p53 through its C-terminal 
domain as well as DNA binding domain and 
enhances DNA binding of p53 to its cognate 
sites which induce p53 driven transcription 
and thereby apoptosis (15,16). Although, 
interaction of PC4 and p53 is critical for 
PC4 mediated activation of p53 function, 
PC4 assisted DNA bending also 
significantly contributes in the enhancement 
of DNA binding of p53 as well as its 
downstream function.  
PC4 is subjected to various 
posttranslational modifications. It gets 
acetylated by another coactivator, p300 and 
phosphorylated by casein kinase II. 
Acetylation enhances its dsDNA binding 
ability. Interestingly, phosphorylation of 
PC4 inhibits acetylation by p300 and hence, 
its double stranded DNA binding ability 
(9,16,17). However, little is known about 
how p53 post-translational modifications 
affect p53-PC4 interaction. Recently, it has 
been discovered that PC4 is a p53 
responsive gene, which established the first 
known positive loop in the regulation of p53 
function (18). If post-translational 
modifications of p53 affect p53-PC4 
interaction, it may indicate presence of other 
regulatory networks, preceding gene 
expression. In order to first understand the 
mechanism of PC4 and p53 interaction from 
a structure-function perspective, and its 
correlation with the downstream effect in 
PC4 mediated activation of p53 function, we 
have investigated the structural components 
involved in the PC4-p53 interaction by 
employing NMR spectroscopy and other 
biophysical techniques. We have employed 
synthetic peptides corresponding to various 
parts of the C-terminal region extensively. 
Since it is difficult and perhaps impossible 
to obtain the whole protein with defined 
acetylations, peptide models are only 
approach to study the effect of acetylation. 
Similar approaches have yielded important 
results for phosphorylation dependent 
effects (19). This approach is better suited 
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for this region of p53 as it is likely to be not 
part of a distinctly folded domain. Although 
the indicative results in some cases were 
obtained from peptide models, the results 
have been validated through different 
functional experiments. This clearly 
suggests that specific amino acid residues of 
PC4 interacts with a very specific domain of 
p53 resulting in the downstream effects. 
Importantly, we identify a crucial 
acetylation that enhances p53-PC4 
interaction.  
Experimental Procedure 
Materials----Ni-NTA Sepharose, Heparin-
Sepharose, Glutathione-Sepharose, 
Benzamidine-Sepharose, SP-Sepharose and 
pre-packed FPLC columns Superdex-75 
were from GE Healthcare. PMSF was from 
Sigma Chemical Company (St. Louis, MO, 
USA). Reduced glutathione was from JT 
Baker. 15NH4Cl and d5-Glycine were from 
Cambridge Isotope Laboratory. 5(6)-
carboxy-fluorescein was from 
Novabiochem. Thrombin was from GE 
Healthcare. T4 Polynucleotide Kinase was 
from Bangalore Genei. All other chemicals 
used were of analytical grade.    
Site-directed mutagenesis----The point 
mutants of PC4-His6, PC4S73A and 
PC4Q65A,  point mutant of  FLAG tagged 
PC4, PC4S73A and PC4Q65A, point mutant 
of  GST p53, p53K381A, p53K382A, 
p53L383A and p53H387A were made by 
the site-directed mutagenesis technique 
(QuikChange II XL site-directed 
mutagenesis kit; Stratagene) as per the 
manufacturer’s instructions. Mutants were 
confirmed by sequencing.  Expression and 
purification of the mutant proteins were 
carried out as described for wild type 
proteins below.  
Purification of proteins----For NMR and 
other biophysical experiments the protein 
was purified according to following 
protocol. The pET28b plasmid encoding the 
protein was transformed in BL21(DE3) and 
the cells were grown in Luria broth 
containing 25 µg/ml of kanamycin at 370C 
at 180 rpm until the A600 reached 0.5-0.6.  
For PC4 the cells were induced with 0.7 mM 
IPTG at 37ºC for 3 h.  Cells were harvested 
by centrifugation. The harvested cells were 
re-suspended in 20 mM Tris-HCl buffer, pH 
7.4 containing 200 mM KCl, 25 mM 
imidazole, 5 mM β-Me, 10% glycerol and 1 
mM PMSF. Cells were sonicated on ice and 
the lysate was cleared by centrifugation 
(14,000 rpm, 30 min, 4oC). Affinity 
chromatographic purification of this protein 
was done using Ni-NTA Sepharose column. 
The pooled fractions from the Ni-NTA 
column was dialyzed against BC200 buffer 
(20  mM Tris-HCl buffer, pH 7.4 containing 
200 mM KCl, 0.2 mM EDTA, 10 mM β-Me 
and 10% glycerol). The protein was then 
loaded onto Heparin-sepharose column 
which was pre-equilibrated with BC200 
buffer. The column was subsequently 
washed with BC200 buffer and the protein 
was eluted by BC400 buffer (20 mM Tris-
HCl buffer, pH 7.4 containing 400 mM KCl, 
0.2 mM EDTA, 10 mM βMe and 10% 
glycerol). The protein was then concentrated 
by polyethylene glycol 20000, dialyzed 
against 20 mM Tris-HCl buffer, pH 7.4 
containing 200 mM KCl, 0.2 mM EDTA, 10 
mM β-ME and 10% glycerol. Gel filtration 
was done on Superdex-75 in FPLC (only for 
preparation of NMR sample). The purity of 
the protein was checked by SDS-PAGE 
followed by Coomassie blue staining. 
Concentration of the protein was determined 
by BCA protein assay. For the purification 
of 15N labeled PC4 the same protocol was 
followed except first cells were grown in LB 
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medium then transferred to M9 medium 
containing 15NH4Cl. 
For GST pull-down and other 
functional assays, the following protocol 
was used. Full-length PC4 and its point 
mutants were purified by Ni-NTA affinity 
chromatography followed by Heparin-
Sepharose affinity chromatography. The 
proteins, expressed and purified from 
bacteria, were analyzed on 12% SDS-PAGE 
and visualized with Coomassie staining and 
confirmed by immunoblotting using PC4 
antibody. FLAG-tagged p53 was bacterially 
expressed and purified using M2-agarose 
immunoaffinity chromatography. GST-p53 
and its point mutants were expressed and 
purified using Glutathione Sepharose 
affinity chromatography.  
GST pull-down assay----GST pull-down 
assays were performed as described 
previously (15). Briefly, 1 µg of GST, GST-
p53, or GST-p53 point mutants bound to 
Glutathione Sepharose beads were incubated 
with bacterial lysate containing 200 ng of 
PC4 or its point mutants in a reaction 
mixture of 200 µl BC150 buffer (20 mM 
Tris HCl, pH 7.4 containing 20% glycerol, 
0.2 mM EDTA and 0.1% NP-40) containing 
150 mM KCl at 4°C for 3 h. The beads were 
then washed five times with BC150 and 
were run on 12% SDS-PAGE gels, followed 
by immunoblotting with PC4 antibody.  
Elecrophoretic Mobility Shift Assay 
(EMSA)---A 36-mer oligonucleotide 
containing p53 binding sites (5’-
TATGCCACGCCCAGGCTTGTCTCTAA
CTTGTGAGCC-3’) derived from the Bax 
promoter was labeled by using T4 
polynucleotide kinase. The radiolabeled 
strand was annealed with the 
complementary strand, and an EMSA was 
performed as described previously (16). 
Briefly, 3 ng of radiolabeled probe was 
incubated in a reaction volume of 40 µl 
containing 8 µl of 5X EMSA buffer (100 
mM HEPES buffer, pH 7.9 containing 125 
mM KCl, 0.5 mM EDTA, 50% glycerol and 
10 mM MgCl2), 2 µl of 60-µg/ml double-
stranded poly dI-dC, 4 µl of bovine serum 
albumin (BSA) (1 mg/ml) and 2µl of 10 mM 
DTT with the proteins as indicated for 30 
minutes at 30°C. The samples were analyzed 
on 5% native PAGE in 0.5X Tris-Borate-
EDTA buffer, pH 8.0 containing 0.05% NP-
40 and electrophoresed at 4°C for 2 hours 
(200V). The gels were dried and DNA-
protein complexes were visualized by 
PhosphorImage Analyzer (Fuji) using Image 
Gauge software. Band quantification was 
done using Phosphor Imager densitometry 
scanning software.  
Luciferase assay----The p53 null human 
carcinoma cell line H1299 were maintained 
at 37°C in Dulbecco’s modified Eagle 
medium with 10% fetal bovine serum. The 
mammalian expression constructs of p53, 
and PC4 used in this study were placed 
under a cytomegalovirus (CMV) promoter. 
The p53-responsive promoter PG13Luc 
contains 13 consensus p53-binding sites in 
tandem followed by a polyomavirus 
promoter, which drives the luciferase gene. 
This construct was used to monitor the 
effect of PC4 on p53-mediated gene 
expression in vivo. The CMV-driven ß-
galactosidase (pCMV-ß gal) construct was 
used as an internal control. Prior to 
transfection, cells were seeded at 0.6-1 x 106 
cells per 30-mm-diameter dishes and 
transfected with different plasmid 
constructs, using Genejuice (Novagen) 
according to the manufacturer’s protocol. 
An empty vector was used to keep the total 
amount of DNA constant in each 
transfection. Luciferase and ß-galactosidase 
activities were measured 24 h after the 
transfection with luciferase assay and ß-
galactosidase assay systems according to the 
procedure provided by manufacturer 
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(Promega). The transient transfection assay 
was performed three times independently to 
monitor average relative luciferase activity 
(15).  
 
Purification of p53 (364-393)-----The 
plasmid encoding the protein GST-p53 C-
terminal (364-393) was transformed into 
BL21(DE3) and the cells were grown in 
Luria broth containing 100 µg/ml of 
ampicillin at 37oC until A600 reached 0.4-
0.5. For expression of p53CT, the cells were 
cooled to 25oC and induced with 1 mM 
IPTG for 3 h. Cells were harvested by 
centrifugation. The cell pellet was 
suspended in 10 mM Tris-HCl buffer, pH 
7.5 containing 100 mM KCl, 0.1 mM 
EDTA, 1% TritonX-100, 5% glycerol and 1 
mM PMSF. Cells were sonicated on ice and 
the lysate was cleared by centrifugation 
(14,000 rpm, 30 min, 4oC). The supernatant 
was loaded onto GST-sepharose (GE 
Healthcare) column which was pre-
equilibrated by lysis buffer. The column was 
washed subsequently with lysis buffer. The 
GST-tagged fusion protein was eluted by 
100 mM Tris-HCl buffer, pH 7.5 containing, 
50 mM KCl, 5% glycerol and 20 mM 
Glutathione. The purified protein was 
dialyzed against 1X PBS (pH 7.5) and 5% 
glycerol. Then the protein was digested with 
thrombin at 22oC, for one and a half hrs and 
loaded onto benzamidine Sepharose (GE 
Healthcare) column which was pre-
equilibrated by 1X PBS, pH 7.5 containing 
5% glycerol for removal of thrombin. The 
digested protein then was loaded onto SP-
sepharose (GE Healthcare) column which 
was pre-equilibrated with 1 X PBS 
containing 5% glycerol to remove GST 
protein. Then the p53 (364-393) protein was 
eluted by using a 0-1 M KCl gradient in 
1XPBS. The eluted fractions were pooled 
and concentrated by polyethylene glycol 
20000, dialyzed against 0.1% acetic acid and 
purified by HPLC using reverse phase C18 
column (Hypersil gold, Thermo Fisher) and 
the mass was checked by ESI (Waters). For 
the purification of 15N  labeled p53 (364-
393) the same protocol was followed except 
first cells were grown in LB medium then 
transferred to M9 medium containing 
15NH4Cl. 
 
Peptide synthesis and purification----All 
peptide nomenclature and corresponding 
sequences are shown in Table I. All the 
peptides were synthesized on a 0.1-mmol 
scale by using a solid-phase peptide 
synthesis strategy using 9-fluorenylmethoxy 
carbonyl chemistry and Rink amide MBHA 
resin. Cleavage of the peptides from Rink 
amide MBHA resin and removal of all side 
chain-protecting groups were achieved in 
94.5% trifluoroacetic acid, 2.5% water, 
2.5% 1, 2 ethanedithiol and 1% 
triisopropylsilan solution. The crude 
peptides were purified by reversed-phase 
high-performance liquid chromatography 
(Waters Associates) with a C18 column 
(Hypersil gold, Thermo Fisher) with linear 
gradients of water/acetonitrile containing 
0.1% trifluoroacetic acid. Peptides masses 
and purity (>95%) were checked by ESI 
(Waters Inc.) and MALDI-Mass 
spectrometry.  
 The selectively deuterated peptide 
was synthesized on 0.1mmole scale by solid 
phase peptide synthesis strategy using Fmoc 
chemistry and rink amide MBHA resin. The 
Lys381 had an ivDde side chain protection 
group. After the synthesis of the peptide, the 
N-terminal –NH2 group was cleaved with 
20% piperidine and then blocked with Boc 
using Boc-anhydride. The side chain 
protecting group ivDde of the Lys381 was 
then removed with 2% hydrazine and the 
exposed side chain –NH2 was acetylated 
with deuterated acetic acid by normal 
carbodiimide coupling strategy. Finally, the 
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peptide was cleaved from the resin and 
removal of all side chain protecting groups 
were achieved in 94.5% trifluoroacetic acid, 
2.5% water, 2.5% 1, 2 ethanedithiol and 1% 
triisopropylsilan solution. The crude peptide 
was purified by reversed-phase high-
performance liquid chromatography (Waters 
Associates) with a C18 column (Hypersil 
gold, Thermo Fisher) with linear gradients 
of water/acetonitrile containing 0.1% 
trifluoroacetic acid. Peptide mass and purity 
(>95%) was checked by MALDI-Mass 
spectrometry. 
 
Peptide labeling----The peptides p53(380-
386), p53(380-386, K381A, K382A, 
L383A), p53(380-386, K381KAc), p53(380-
386, K382KAc) and p53(380-
386,K386KAc)  were labeled with 5,6-
carboxy fluorescein in solid phase. Dry resin 
bound N-terminal deprotected peptide (3 
µmole) reacted with 10 times molar excess 
of 5(6)-carboxy fluorescein, HBTU (1:1) 
and 20 times molar excess of N-
ethyldiisopropylamine in DMF. The reaction 
was kept for 4 hours in dark at 250C. After 
completion of the reaction, resin was 
washed thoroughly with 20% piperidine in 
DMF until the wash solution becomes 
colorless. Resin was then washed 
consecutively with DMF and Et2O for five 
times and finally dried under N2 atmosphere. 
After labeling peptides were cleaved as 
unlabeled peptides and purified by HPLC 
and masses were checked by Mass 
Spectrometer. 
NMR spectroscopy----All the NMR 
experiments were conducted at 37oC on a 
600 MHz Bruker Biospin NMR 
spectrometer using TCI cryoprobe. The 
buffer was 50 mM KP, pH 6.2 containing  
100 mM KCl. The 1D proton spectra were 
recorded using the pulse program zgesgp 
and water suppression achieved with 
excitation sculpting. TOCSY (mixing time 
60 ms) spectra were recorded with solvent 
suppression using WATERGATE and the 
spinlock in TOCSY experiment was attained 
by MLEV sequence. The 1H, 15N HSQC 
spectra were recorded using the pulse 
program hsqcetfpf3gp with flip back pulses 
and optimized SP1 with ‘gs’. The resonance 
assignment of PC4 was taken from 
published data (20).  
Edited NOESY----The 1H, 15N isotope-edited 
NOESY spectra was recorded using the 
pulse program noesygpphwgx1 with mixing 
time 400 ms and solvent suppression was 
achieved using WATERGATE. The isotope-
edited NOESY was conducted in 50 mM 
Potassium phosphate buffer, pH 6.2 
containing 50 mM KCl and 50 mM d5 
glycine. Reference (21).  
 
Fluorescence anisotropy experiments---- 
Fluorescence anisotropy measurements 
were performed at 40C by using 
Quantamaster 6 (PTI) T-geometry 
fluorometer. The titrations were carried out 
in 20 mM Tris-HCl buffer, pH 7.4 
containing 100 mM KCl, 0.2 mM EDTA, 
20% glycerol and 0.1% NP40. 
Fluorescence anisotropy was measured 
with excitation at 490 nm and emission at 
530 nm using bandwidths of 5 nm on both 
sides. For competition experiments, the 
titrations were carried out in same solution 
conditions as above. 4 nM labeled 
p53(380-386) peptide was incubated with 
saturating concentration of PC4 at 4oC for 
half an hour and then titrated with 
unlabeled p53(380-386) and p53(380-386, 
K381A, K381A, L383A).   
 
 
Sedimentation velocity----Sedimentation 
velocity measurements were performed at 
40C in 20 mM Tris-HCl buffer, pH 7.4 
containing 100 mM KCl, 0.2 mM EDTA, 
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20% glycerol and 0.1% NP40 at the rotor 
speed 38000 rpm using Beckmann coulter 
analytical ultracentrifuge (Proteomelab XL-
A/XL-I). Scan was recorded at 495 nm and 
data was fitted dc/dt vs. s* in Origin 6 using 
sedimentation time derivative analysis. 
Equations described in the vendor’s 
software package was used. Peptide and 
protein concentrations were 5 µm each.  
 
Statistical and Computational Methods----
The standard errors were obtained from 
three or more independent measurements. 
For fluorescence anisotropy measurements, 
the binding isotherms were fitted to a single 
site binding equation: 
 
Aobs = A0 +  
 
[(A∞-A0).{(Kd+X+[pep])-√((Kd +X+[pep])
2
-4.X.[pep])}] 
  2[pep] 
 
Where, Aobs is the observed anisotropy, A0 
is the initial anisotropy, A∞ is the final 
limiting anisotropy, [pep] is the labeled 
peptide concentration in Molar units, X is 
the total PC4 concentration and Kd is the 
dissociation constant in Molar units. The 
binding model makes no a priori 
assumptions except that there is only one 
binding site for the p53 peptide per subunit 
of PC4 and the binding is independent of 
whether another peptide is bound to the 
neighboring subunit or not.  
 
Results 
In the last few years, PC4 has 
emerged as an important regulator of many 
p53 target genes (16). However, little is 
known about how PC4 mediates the 
transcription of p53 target genes. In previous 
articles, it was demonstrated that the C-
terminal region (negative regulatory 
domain) of p53 is most important for this 
interaction, although the exact mechanism is 
unclear (16). In order to gain more structural 
information, we have attempted to identify 
the amino acids responsible for this 
interaction.  
p53(380-386) region is crucial for 
interaction with PC4 
 p53 has a modular structure (22). 
Figure 1 (A) shows the different regions of 
p53 along with their major functions. Many 
of these functions are modulated by post-
translational modifications. This modular 
nature often implies that peptides derived 
from these regions are capable of interacting 
with partner proteins as well. At first, p53 
(364-393) was purified as a GST fusion 
protein, followed by cleavage and 
purification of the pure peptide. Chemical 
shift perturbation was used to identify the 
possible interacting regions. The whole 
spectra were difficult to assign and here we 
focus only on the methyl region of the 
TOCSY spectra. Figure 1 (B) shows the 
methyl region of the TOCSY spectra of the 
p53 (364-393) with and without the full-
length sub-stoichiometric amount of PC4 
and only peptide protons are observable 
under this conditions. The TOCSY spectra 
with and without PC4 reveal a number of 
chemical shift changes; thus, indicating 
interaction of the peptide and the protein 
(data not shown). This peptide contains two 
leucine residues, 369 and 383, and no 
isoleucine residues, thus making it easier to 
identify leucine methyl resonances from 
chemical shift data alone. Of the two leucine 
methyl peaks in the 0.8-1.0 ppm region in 
the TOCSY spectra, one shows significant 
chemical shift change but the other doesn’t; 
clearly indicating that either region around 
369 or 383 is responsible for binding to 
PC4. To identify which region is responsible 
for PC4 binding, we synthesized two 
peptides p53 (366-372) and p53 (380-386) 
and the binding was studied by chemical 
shift perturbation in the presence or absence 
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of PC4. Comparison of chemical shifts of 
methyl protons indicates no significant shift 
occurs for p53 (366-372) (Figure 1 (C)). 
However, significant chemical shift change 
is seen for L383 methyl group p53 (380-
386), indicating significant interaction of 
this region with PC4 (Figure 1 (D)). This 
interaction pattern was verified using a GST 
pull-down assay. The results suggest that the 
mutation at the lysine 382 residue of p53 
substantially reduces its interaction ability 
with PC4 (Figure 1 (E), lane 3 versus lane 
5). On the other hand, the effect of mutation 
at histidine 387 exhibited a moderate level 
of interaction and the mutation at lysine 381 
residue affected the interaction minimally 
(Figure 1 (E), lane 3 versus lane 7 and 4) 
supporting the conclusion that 380-387 
region of p53 is responsible for interaction 
with PC4 (Figure 1 (E)). 
 We have verified the interaction of 
this region of p53 with PC4 by two different 
biophysical techniques: Analytical 
ultracentrifugation and fluorescence 
anisotropy. Figure 2 (A) and (B) show 
sedimentation velocity profile of fluorescein 
labeled p53 (380-386) monitored at 495 nm, 
in the absence and presence of PC4, 
respectively. The analysis gave a value of 
Svedberg constant (Sapp; uncorrected for 
viscosity and temperature) value of 1.05 not 
inconsistent with the size of a small peptide. 
In the presence of PC4, the parent Sapp peak 
largely disappears, indicating loss of the free 
peptide. There are several new species of 
higher S values. This could be due to 
peptide bound to different oligomeric states 
of PC4. The lowest sedimentation value of 
these different species is 2.95, which most 
likely originates from the PC4 dimer. The 
other higher sedimenting species probably 
are higher order oligomers of PC4. The 
analytical ultracentrifugation supported the 
interaction of PC4 with 380-386 region of 
p53. To obtain a more quantitative measure 
of the p53-PC4 interaction, we have 
determined the binding isotherm by 
fluorescence anisotropy. Figure 2 (C) shows 
the binding isotherm of fluorescein labeled 
p53 (380-386) with PC4. The binding 
isotherm shows saturation behavior and 
when fitted to a single site binding equation 
it yields a dissociation constant of 2.02 + 
0.69 nM. From the previous GST pull-down 
assay it was clear that lysine and leucine 
residues in this stretch of amino acids 
probably play a crucial role in the binding, 
we synthesized a KKL381, 382, 383 AAA-
p53 (380-386) peptide. Binding of 
fluorescein labeled triple alanine substituted 
peptide with PC4 was monitored by 
fluorescence anisotropy and the binding 
isotherm is also shown in Figure 2 (C). It is 
clear from the profile that in contrast to the 
wild-type peptide, no increase in anisotropy 
was seen--- indicating that no significant 
binding occurs in the concentration range 
studied. Clearly, at least one of the three 
residues is important for p53 interaction 
with PC4. In order to confirm that 
modification of N-terminal end in no way 
affects the results reported above, we have 
done competition experiments with the 
unlabeled peptide. When the PC4 was first 
allowed to form a complex with Fluorescein 
labeled p53 (380-386) and then titrated with 
either unlabeled p53 (380-386) or unlabeled 
KKL381, 382, 383 AAA p53 (380-386) the 
anisotropy quickly returns to the free peptide 
level for the former but stays unchanged for 
the latter (Figure 2 (D)). This clearly 
indicates that modification of the N-terminal 
α-amino group has no significant effect on 
the binding of the peptides.  
Acetylation of Lysine 381 and 382 
enhances p53-PC4 interaction 
It was established previously that 
acetylation of both PC4 and p53 enhance 
their interactions. However, little is known 
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about the identity of the residues that are 
involved in this interaction. This is 
important as it is already established that 
acetylation of different lysine residues in 
p53 produces different functional outcomes. 
We have thus used the fluorescence 
anisotropy technique to study the interaction 
of p53 (380-386) with PC4 as described 
before. In these experiments, bacterially 
produced recombinant PC4 was used and 
thus assumed to be not post-translationally 
modified. Figure 3 shows the binding 
isotherms of p53 (380-386) acetylated in 
either K381 or K382 or K386, respectively 
with PC4. The binding isotherm was fitted 
to a single binding site to yield a 
dissociation constant of 0.52 + 0.18, 0.94 + 
0.29 and 1.58 + 0.36 nM respectively. The 
error analysis reported here are obtained 
from 4-5 separate experiments done under 
identical conditions and statistical analysis 
was performed from Kds obtained from 
individual experiments. This indicates that 
both K381 and K382 acetylation enhances 
the binding affinity of p53 (380-386). Figure 
3 also shows the binding isotherm of triply 
acetylated p53 (380-386) [K381, K382, 
K386] with PC4. The obtained dissociation 
constant is 0.35 + 0.16 nM, which indicates 
some additive effect.  Thus, acetylation of 
K386 appears to have no role in 
strengthening interaction with PC4.  
p53 (380-386) peptide inhibits p53-PC4 
interaction in cell 
 Since, p53 (380-386) has a high 
affinity for PC4, it may be possible to direct 
it to the nucleus and inhibit PC4 mediated 
activation of p53 target genes. We have thus 
attached a cell penetration tag to this peptide 
(hexa D-arginine) and a nuclear localization 
signal (NLS) and attempted to find out the 
effect of this peptide to PC4 mediated 
activation of p53. First, we have attempted 
to find out if the peptide enters the cell 
nucleus. N-termini of both the peptides were 
labeled in the solid phase with fluorescein 
and the fluorescein modified peptide was 
used in confocal fluorescence microscopy 
for localization. Both the peptides are 
largely concentrated in the nucleus 
(Supplementary Figure 1). We have used the 
same luciferase construct described before 
to study the effect of these peptides in the 
p53-PC4 interaction in the p53 mediated 
transactivation. As expected, PC4 in the 
presence of p53 could stimulate 
transactivation from pG13Luc promoters 
significantly while the activation was 
completely abolished by the wild-type 
peptide. However, almost no effect of the 
KKL 381, 382, 383 AAA-p53 (380-386) 
was observed, indicating specificity of the 
effect (Figure 4).  
Serine-73 of PC4 plays an important role 
in p53-PC4 interaction 
 The PC4 protein consists of two 
functional domain of roughly equal size. 
The N-terminal half appears to be largely 
flexible and contains much of the regulatory 
post-translational modification sites. The C-
terminal half binds to single stranded DNA 
and is also responsible for dimerization 
(Figure 5 (A)). The crystal structure of the 
C-terminal half of PC4 has recently been 
reported (23). We have attempted to 
elucidate the p53 interaction interface of 
PC4 by chemical shift perturbation using 
HSQC spectra. The HSQC spectra of PC4 
has been assigned under low pH condition, 
previously (20). We have first attempted to 
obtain the HSQC spectra under more 
physiological conditions. At around the 
neutral pH, the spectra is not as well 
behaved but the pattern is very similar to the 
low pH spectra. One-to-one mapping of 
important resonances can be established and 
we have used this procedure to assign the 
spectra at around the neutral pH. Since it is 
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already known that the extreme C-terminal 
region of p53 is the most important 
interaction site, we have chosen p53 (380-
386) for HSQC studies. Two versions of this 
peptide was used to obtain differential 
chemical shifts. One version of the peptide 
was acetylated at K381, K382 and K386, 
while the other contained three alanines at 
positions 381, 382 and 383. Advantage of 
using these peptides is that one binds with 
very high affinity and the other is at best a 
very weak binder, if at all. Overlap of the 
two HSQC spectra showed significant 
chemical shift changes for some resonances 
in the (Figure 5 (B)), but not for most. Only 
the distinctly resolved region is shown. Two 
of the most clearly identified resonances that 
show the largest shifts are Serine-73 and 
Glutamine-65. Since the cause of chemical 
shift perturbation could be due to direct 
interaction or indirect change in the 
environment due to interaction, we have 
mutated both these residues to find out their 
role in the p53 interaction. The GST pull-
down assay, as described earlier, (15) was 
used to estimate the interaction strength of 
PC4S73A and PC4 Q65A (Figure 6 (A) and 
(B)) with p53 fusion protein. It is clear from 
the pull-down assay that S73A substitution 
affects the interaction significantly, whereas, 
Q65A mutation has little effect. This 
indicates that Serine-73 plays an important 
role in p53 interaction. This was confirmed 
by a fluorescence anisotropy assay 
(previously described) in which p53 (380-
386) was fluorescein end-labeled and 
titrated with full-length PC4. The wild-type 
PC4 titration previously showed significant 
increase in fluorescence anisotropy 
indicating binding (Figure 2 (C)). However, 
for PC4S73A, no increase in fluorescence 
anisotropy was seen, indicating no 
significant binding in the concentration 
range studied (Figure 6 (C)). 
 The functional effects of S73A 
mutation in PC4 was tested in an in vivo 
gene expression activation assay using 
luciferase as the reporter gene in p53-/- 
H1299 cells. PG13Luc construct in which 
the luciferase gene is under the control of a 
promoter with 13 binding sites of p53 was 
used. PC4 in the presence of p53 could 
stimulate transactivation from pG13Luc 
promoter significantly (about 5 fold) as 
compared to transfection of p53 alone as 
reported earlier (Figure 6 (D), compare lane 
2 versus lane 6). The vector control and PC4 
alone showed negligible luciferase activity. 
Co-transfection of p53 with PC4Q65A was 
found to activate transcription from 
pG13Luc (about 4.8 fold as seen in Figure 6 
(D); compare bar 2 versus bar 7) as 
compared to transfection of p53 alone, 
while, co-transfection of p53 with PC4S73A 
showed reduced transactivation (Figure 6 
(D); compare bar 2 versus bar 8) from 
pG13Luc (about 2.4 fold).  
 PC4 directly interacts with p53 and 
enhances the DNA binding of p53 to its 
cognate sites. In order to investigate the 
functional significance of S73 mediated 
interaction of PC4 with p53, EMSA was 
performed using PC4S73A mutant and 
FLAG-tagged p53. The EMSA analysis 
showed that FLAG-p53 formed a sequence-
specific complex, and as expected, the 
addition of wild type PC4 enhanced p53-
mediated DNA binding in a dose-dependent 
manner (Figure 7 (A); lanes 3-6). In 
agreement with the results of the interaction 
studies, we found that PC4S73A mutant, 
which showed very weak interaction with 
p53, activated p53 DNA binding minimally 
(Figure 7 (A); lanes 3-6 versus lanes 7-10). 
The quantification of the EMSA data, 
indicated that at the concentration 
corresponding to 80 ng addition, wild type 
PC4 could enhance p53 DNA binding more 
than 2.5 fold as compared to the p53 
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interaction deficient point mutant PC4S73A 
(Figure 7 (B)). 
 The p53 region consisting of amino 
acids 380-386 may bind in the proximity of 
Serine-73. However, the mutagenesis 
experiments is not an unequivocal indication 
of the presence of the mutant residue in the 
binding site, as the mutation of a residue can 
exert a long-distance effect.  
We have thus attempted to identify 
which residues may be present close to the 
bound 380-386 amino acid residues of p53 
through intermolecular nuclear Overhauser 
effect. For this experiment, 15N labeled PC4 
was complexed with different acetylated p53 
(380-386) peptide and edited 2D NOESY 
experiment was performed. In this 
experiment, only the NOEs from unlabeled 
protons to the protons attached to 15N atoms 
are seen. We performed this experiment 
with 15N-PC4 alone and in the presence of 
unlabeled triply acetylated p53 (380-386) as 
well as all the single acetylated peptides. 
Any additional NOE seen here is likely to 
originate from the peptide protons to the NH 
protons of PC4. We primarily focused on the 
acetyl peaks which are clearly 
distinguishable. We were able to clearly 
distinguish one NOE from acetyl group of 
lysine 381 to an amide proton (data not 
shown). To confirm this, we have 
synthesized the same peptide with 
deuterated acetyl group on lysine 381. 
Overlap of the protonated and deuterated 
K381Ac/15N-PC4 complex, clearly shows an 
additional NOE from the protonated acetyl 
group to an amide group (Figure 8). 
Comparison of this NOE with HSQC done 
under identical conditions suggests that this 
residue is aspartate-76. This indicates 
presence of aspartate-76 in the binding 
pocket, close to lysine 381.  
Discussion 
 Positive coactivator 4 or PC4 was 
originally isolated as a general transcription 
coactivator (9). Recent work suggests that it 
may play an important role in DNA repair 
and replication as well. A number of studies 
have pointed towards its important role in 
the activation of genes targeted by p53 (10). 
It is known to interact with p53 mainly 
through its C-terminal DNA binding domain 
(16). Apparently contradictory results have 
been reported about the location of the part 
of p53 that interacts with PC4. Initial reports 
suggest that PC4 interacts with both the C-
terminal negative regulatory domain of p53 
and the DNA binding domain and was 
supplemented by a recent report that it 
interacts with the N-terminal transactivation 
domain only (24). In this article, we have 
conclusively demonstrated binding of PC4 
with 380-386 region of p53 which is 
modulated by acetylation of critical lysine 
residues (K382 and K381). The binding is at 
least two to three orders of magnitude 
stronger than the dissociation constant 
reported by Fersht and coworkers with full-
length bacterially produced p53 (24). The 
high affinity for the 380-386 peptide 
reported here is consistent with conclusions 
of our previous work that major interaction 
with p53 occurs through the negative 
regulatory domain (16). Single point 
mutants obtained here and the functional 
assays with the single point mutants and 
chemical genetics approach with the p53 
(380-386) peptide confirmed the role of 
negative regulatory domain’s involvement in 
p53-PC4 interaction. It is not clear why 
bacterially produced full-length p53 did not 
bind with higher affinity, but could be due to 
differently folded nature of the full-length 
p53, when produced in E.coli.  
 NMR and mutagenesis experiments 
indicated that Serine-73 plays a crucial role 
in the interaction. Intermolecular NOE 
detected in 2D-NMR experiment suggested 
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that the K381 acetyl groups may be in close 
proximity with aspartate-76. Figure 9 shows 
the crystal structure of PC4 (bound to single 
stranded DNA) with the two residues 
highlighted. Both the residues are located in 
a trough away from the DNA binding region 
of PC4. This suggests that this region may 
bind p53 negative regulatory domain. The 
many-pronged approach reported here 
conclusively proves that wild-type p53-PC4 
interaction occurs through the C-terminal 
regulatory region of p53. In a previous 
article, Banerjee et al., have demonstrated 
that p53∆30 (p53 without the last 30 amino 
acids) retains most of the activation potential 
of PC4 (15). Those results seem to be 
apparently contradictory to the present 
results as well as other results consistent 
with the present results. Apart from the 
structural data, the peptide inhibition results 
presented here strongly suggests that the 
wild-type p53-PC4 interaction resulting in 
activation of gene expression occurs 
primarily through the residues 380-386 of 
p53. Batta et al., had reported that the DNA 
binding domain of full-length p53 has weak 
PC4 interacting potential (16). The most 
likely explanation of activation by p53∆30 is 
that in the full-length p53, the interaction 
with PC4 primarily occurs through the 
residues 380-386 and its deletion causes a 
conformational change in the DNA binding 
domain resulting in a stronger interaction 
with the interaction patch present in the 
DNA binding domain.  
In the peptide model, acetylation of 
lysine-381 and 382, together led to an order 
of magnitude increase of affinity suggesting 
that acetylation may play a crucial role in 
the coactivation function of PC4. It has been 
previously established that acetylation of 
lysine-382 is crucial for full activation of 
p53 initiated pro-apoptotic transcription 
program (25,26). However, the mechanism 
of this acetylation dependence is not known. 
Significant enhancement of p53-PC4 
interaction clearly provides a mechanism by 
which acetylation of lysine-382 modulates 
the p53 dependent target gene expression 
and pro-apoptotic response. However, this 
needs to be verified by direct experiments. 
Acetylation of PC4 by p300 has been shown 
to enhance double stranded DNA binding 
activity of PC4, resulting in enhanced 
activation function (16). Due to difficulty in 
obtaining single specifically acetylated p53, 
only plausible way at this time to understand 
the role of individual acetylations is through 
peptide models. However, information 
obtained from peptide models cannot readily 
be extended a priori to in vivo role of such 
post translational modifications and may 
only be thought of as indicative. However, 
peptide models employed to understand the 
post-translational modifications in N-
terminal domain of p53 yielded a wealth of 
information which has largely been verified 
later (19). 
 If acetylation of K382 and K381 of 
p53 by p300 enhances the p53-PC4 
interaction in vivo as suggested by peptide 
models, then activation of p300 may cause a 
synergistic activation of p53 targeted genes. 
In this study, it was demonstrated that 
peptide models could provide useful 
information regarding roles of post-
translational modifications and show that 
PC4 could be an important partner in 
translating gene regulatory functions of p53.  
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phosphate; DMF: N,N-Dimethyl formamide; WATERGATE: Water suppression by Gradient-
Tailored Excitation; EMSA: Electrophoretic Mobility shift assay; NOE: Nuclear Overhauser 
Effect; TOCSY: Total Correlation Spectroscopy 
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 Figure Legends 
 
Figure 1. (A) Domain structure of p53. (B) Overlap of methyl region TOCSY spectra of p53 
(364-393) alone (blue) and p53 (364-393) in the presence of PC4 (10:1) (red). (C) Overlap of 1D 
spectra of methyl region of p53 (366-372) alone (blue) and p53 (366-372) in the presence of PC4 
(7:1) (red). (D) Overlap of 1D spectra of methyl region of p53 (380-386) alone (blue) and p53 
(380-386) in the presence of PC4 (7:1) (red). All the experiments were conducted at 37oC on a 
600-MHz Bruker Biospin NMR spectrometer using TCI cryoprobe. The buffer was 50 mM 
Potassium phosphate buffer, pH 6.2 containing 100 mM KCl. TOCSY (mixing time 60 ms) 
spectra were recorded with solvent suppression, which was achieved using WATERGATE and 
the spinlock in TOCSY experiment was attained by MLEV sequence. (E) GST pull-down assay: 
One microgram of GST (lane 2) or GST-p53 point mutant proteins (lanes 3 to 7) were incubated 
with bacterial lysate containing 200 ng of PC4 and analyzed by immunoblotting with anti-PC4 
antibody. Lane 1, 20% input of bacterial cell lysate. Intensities relative to the GST only control 
are reported at the bottom.  
Figure 2. Sedimentation velocity run of fluorescein end-labeled p53 (380-386). (A) alone 
(SEDPHAT profile). B. Sedimentation velocity run of fluorescein end-labeled p53 (380-386) 
complex with PC4 (1:1). Scan was recorded at 495 nm. (C) Binding isotherm of fluorescein end-
labeled p53 (380-386) with PC4 (solid diamond) and binding isotherm of fluorescein end-labeled  
p53 (380-386, KKL 381, 382, 383AAA) with PC4 (circles). (D) Effect of unlabeled p53 (380-
386) (open circles) and p53 (380-386, KKL 381, 382, 383AAA) (solid circles) on Fluorescein 
labeled p53 (380-386)/PC4 complex. Fluorescence anisotropy measurements were performed at 
4oC by using a Quantamaster 6 (PTI) T-geometry fluorometer. The titrations were carried out in 
20 mM Tris-HCl buffer, pH 7.4 containing 100 mM KCl, 0.2 mM EDTA, 20% glycerol and 
0.1% NP40. Fluorescence anisotropy was measured with excitation at 490 nm and emission at 
530 nm using bandwidths 5 nm. Further details are given in the Experimental Procedure.  
Figure 3. Binding isotherms of acetylated p53 peptides. Binding Isotherm of (Red) end-labeled 
p53 (380-386, K381Ac); (Green) end-labeled p53 (380-386, K382Ac); (Blue) end-labeled p53 
(380-386, K386Ac) and (Black) end-labeled p53(380-386, KKK381, 382, 386 AcAcAc) with 
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PC4. Fluorescence anisotropy measurements were performed at 4oC by using Quantamaster 6 
(PTI) T-geometry fluorometer. The titrations were carried out in 20 mM Tris-HCl buffer, pH 7.4 
containing 100 mM KCl, 0.2 mM EDTA, 20% glycerol and 0.1% NP40. Fluorescence 
anisotropy was measured with excitation at 490 nm and emission at 530 nm using bandwidths 5 
nm. The anisotropic data were fitted into a single site binding equation as described before (27). 
Figure 4. Inhibition of PC4 enhancement of p53 activation of gene expression by p53 (380-
386). p53-/- H1299 cells were transfected with PG13-Luc (500ng), CMV-βGal (500ng), p53 (200 
ng), PC4 (1.2 µg) in combinations as indicated. After 14 hours of transfection, WT peptide (WT) 
or control peptide (3A) were added in the indicated lanes.  Following 24 hours of transfection, 
the luciferase activity was measured and normalized with β-galactosidase activity.  Error bars 
show the standard errors of means of the replicates. +, present; -, absent. 
Figure 5. Binding of acetylated p53 peptides by NMR. (A) Cartoon drawing of modular 
structure of PC4. (B) Binding of PC4 and p53 (380-386) by NMR spectroscopy (1H, 15N HSQC).    
1H, 15N HSQC overlaps of p53 (380-386, K381A,K382A,L383A)/ 15N-PC4 (1:1) complex (blue) 
and p53 (380-386, K381KAc,K382KAc,K386KAc)/ 15N-PC4 (1:1) complex (red). NMR 
experiments were conducted at 37oC on a 600-MHz Bruker Biospin NMR spectrometer using 
TCI cryoprobe. The buffer was 50 mM Potassium phosphate buffer, pH 6.2 containing 50 mM 
KCl and 50 mM d5 glycine. 
Figure 6. Interaction of p53 (380-386) with mutant PC4. (A) GST pull-down assay of p53 and 
mutant PC4 interaction: One microgram GST-p53 protein was incubated individually with 
bacterial lysate containing 200 ng of either PC4WT or PC4S73A, pulled down as described in 
the materials and methods and analyzed by immunoblotting with anti-PC4 antibody. Lanes 1 and 
2 depicts 20% input of bacterial cell lysate containing PC4WT and PC4S73A, respectively. (B) 
One microgram GST-p53 protein was incubated individually with bacterial lysate containing 200 
ng of either PC4WT or PC4Q65A, pulled-down and analyzed by immunoblotting with anti-PC4 
antibody. Lane 1 and 2 depicts 20% input of bacterial cell lysate containing PC4WT and 
PC4Q65A respectively. (C) Binding isotherm of fluorescein end-labeled p53 (380-386) with PC4 
S73A. Fluorescence anisotropy measurements were performed at 4oC by using Quantamaster 6 
(PTI) T-geometry fluorometer. The titrations were carried out in 20 mM Tris-HCl buffer, pH 7.4 
containing 100 mM KCl, 0.2 mM EDTA, 20% glycerol and 0.1% NP40. Fluorescence 
anisotropy was measured with excitation at 490 nm and emission at 530 nm using bandwidths 5 
nm. (D)  Gene expression activation by wild-type or mutant PC4: p53-/- H1299 cells were 
transfected with PG13-Luc (500ng), CMV-βGal (500ng), p53 (200ng), PC4WT (1.2µg), 
PC4Q65A (1.2µg) or PC4S73A (1.2µg)  in combinations as indicated. Following 24 hours of 
transfection, the luciferase activity was measured and normalized with β-galactosidase activity.  
Error bars show the standard errors of means of the replicates. +, present; -, absent. 
Figure 7. DNA binding by p53 in the presence of PC4. (A) Three nanograms of a γ-32P-labeled 
oligonucleotide containing a p53 binding site was incubated with 50 ng of p53 either in the 
absence of PC4 (lane 2) or with increasing concentrations of PC4 (lanes 3, 4, 5 and 6) or 
PC4S73A (lanes 7, 8, 9 and 10). Lane 1 contains the γ-32P-labeled oligonucleotide alone. + 
present; - absent. (B) Quantitative representation of effect of PC4 and its point mutant S73A, on 
p53-mediated DNA binding. The levels of induction of p53-mediated binding are represented on 
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the y axis, and the increasing concentrations of PC4 or its point mutant PC4S73A on the x axis. 
Error bars are obtained from statistical analysis of multiple experiments.  
Figure 8. Isotope-edited NOESY spectra. Overlaps of isotope-edited NOESY spectra of p53 
(380-386, K381Ac)/PC4 complex (1:1) (blue) and p53(380-386, K381KAc-d3)/PC4 complex 
(1:1) (red). The upper spectra shows the 1H, 15N HSQC of p53 (380-386, K381Ac)-PC4 complex 
(1:1). Experiments were conducted at 37oC on a 600-MHz Bruker Biospin NMR spectrometer 
using TCI cryoprobe. The buffer was 50 mM Potassium phosphate buffer, pH 6.2 containing 50 
mM KCl and 50 mM d5 glycine.   
Figure 9. Depiction of Space filling model of the C-terminal domain of PC4 (pdb id: 2C62). 
The two subunits are in grey and white. Following residues are highlighted: Serine-73 (blue); 
Aspartate-76 (red); Aspartate-84 (green) and glutamine-65 (cyan). The bound ssDNA is in 
wireframe model.  
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Table I 
Sequence and nomenclature of peptides 
 
NOMENCLATURE SEQUENCE 
p53(366-372) SSHLKSK 
p53(380-386) HKKLMFK 
p53(380-386, K381A, K382A, 
L383A) 
HAAAMFK 
p53(380-386, K381KAc) HKAcKLMFK 
p53(380-386, K382KAc) HKKAcLMFK 
p53(380-386, K386KAc) HKKLMFKAc 
p53(380-386, K381KAc, 
K382KAc, K386KAc) 
HKAcKAcLMFKAc 
6-D-Arg-NLS-p53(380-386, 
K381KAc,K382KAc, 
K386KAc) 
DR6PKKKRKVHKAcKAcLMFKAc 
 
6-D-Arg-NLS-p53(380-386) DR6PKKKRKVHKKLMFK 
6-D-Arg-NLS-p53(380-386, 
K381A, K382A, L383A)    
DR6PKKKRKVHAAAMFK 
Acetylated residues are highlighted in bold fonts, DR6 stands for 6-consecutive D-arginine 
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Figure 1 (A)  
R6PKKKRKVHKKLMFK
R6PKKKRKVHAAAMFK
NLS
WT peptide
3A peptide
380 386p53
Transactivation domain
Proline rich region
DNA binding domain Tetramerization domain
C terminal domain
1 61 94 292 325 356 393
 
(B) 
 
(C) 
 
 
 
 
 
(D) 
 
 
 
 
 
 
 
(E)  
 
1 4.7 3.5 2.4 6.4 2.7Fold increase in PC4-p53 
interaction
α PC4
 by guest, on M
ay 29, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
19 
 
Figure 2 
 
(A) 
 
 
 
 
 
 
(B) 
(B) 
 
 
 
 
© 
 
 
 
(C) 
0 2x10-8 4x10-8 6x10-8 8x10-8 1x10-7
0.058
0.06
0.062
0.064
0.066
[PC4] M
An
is
o
tr
o
py
 
(D) 
 
0 1x10-7 2x10-7 3x10-7 4x10-7 5x10-7 6x10-7
0.88
0.9
0.92
0.94
0.96
0.98
1
1.02
[Peptide] M
Re
la
tiv
e
 
An
is
o
tr
o
py
1.0
0.
 
0.25 
1.35 
2.95 
7.4 
8.8 
14.3 
10.8 
 by guest, on M
ay 29, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
20 
 
Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 (A) 
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Figure 8  
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Figure 9  
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